GRM5 and fragile X syndrome: Our results have potential implications for the treatment of FXS as plasma AβPP/Aβ can be readily screened as biomarkers to evaluate potential therapies including mGluR5 antagonists as well as secretase inhibitors and anti-Aβ, which are currently undergoing testing for the treatment AD.